Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 6,214 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $25.03, for a total value of $155,536.42. Following the completion of the sale, the insider owned 21,479 shares of the company’s stock, valued at $537,619.37. This represents a 22.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 1.4%

NASDAQ CSTL traded up $0.36 on Wednesday, reaching $25.19. The company had a trading volume of 394,638 shares, compared to its average volume of 396,369. The stock’s 50 day moving average is $29.30 and its 200-day moving average is $31.96. The stock has a market cap of $748.92 million, a price-to-earnings ratio of -29.64 and a beta of 1.18. The company has a quick ratio of 5.11, a current ratio of 5.26 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 52 week low of $14.59 and a 52 week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15. The business had revenue of $81.88 million during the quarter, compared to the consensus estimate of $81.19 million. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%. Equities analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

CSTL has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Guggenheim increased their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Morgan Stanley upgraded Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. KeyCorp restated an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a report on Thursday, January 29th. Finally, BTIG Research increased their price target on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Castle Biosciences presently has an average rating of “Moderate Buy” and an average price target of $47.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Castle Biosciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after buying an additional 27,511 shares during the period. RTW Investments LP acquired a new position in shares of Castle Biosciences during the fourth quarter worth about $82,283,000. Principal Financial Group Inc. boosted its position in shares of Castle Biosciences by 0.7% during the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after buying an additional 13,289 shares during the period. Portolan Capital Management LLC boosted its position in shares of Castle Biosciences by 1.7% during the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock worth $34,499,000 after buying an additional 25,539 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Castle Biosciences by 7.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock worth $33,564,000 after buying an additional 96,084 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.